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Abstract The author group has previously established an
in vivo subchronic cigarette smoke (CS) exposure rat
model, in which the systemic oxidative burden as well as
the modulation of local anti-oxidative enzymes in the lung
has been demonstrated. Oxidative stress has been shown to
induce pro-inﬂammatory cytokine release, including
interleukin (IL)-6 in the airways. In this study, we aimed to
investigate the changes in IL-6 production, as well as the
oxidative/anti-oxidative responses in the cerebral cortex
using the same in vivo model. IL-6 was determined by
RT-PCR and western-blot analysis. Local oxidative and
anti-oxidative responses were determined by measuring
cerebral cortical malondialdehyde (MDA) and advanced
oxidation protein product (AOPP) levels, superoxide dis-
mutase (SOD) and catalase activities, and the reduced to
oxidized glutathione (GSH/GSSG) ratio. Nitrite level was
measured by ﬂuorescent spectrophotometry. Our results
demonstrated a signiﬁcant increase in both IL-6 mRNA
and protein levels. Reductions of SOD activity and man-
ganese (Mn)SOD protein level were observed together with
the increased level of superoxide measured by chemilu-
minescent signal, after 56 days of CS exposure. There were
no signiﬁcant changes in the cerebral cortical levels of
MDA, AOPP, catalase activity, and the GSH/GSSG ratio.
Nitrite level was signiﬁcantly reduced, together with the
decreased protein level of nNOS in the cerebral cortex,
after 56 days of CS exposure. Our results suggest that
exposure to CS induces IL-6 expression in the cerebral
cortex, which is not mediated by the oxidative/anti-oxida-
tive imbalance.
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Interleukin (IL)-6 is a cytokine that mediates immune
responses and inﬂammation processes. In the 1980s, IL-6
was ﬁrst discovered to be produced by lymphocytes that
mediated differentiation of B-cells (Hirano et al. 1986; Van
Damme et al. 1987). Molecular pathway of IL-6 is initiated
by the binding of IL-6 to its cell surface receptor, which
triggers the recruitment of the signal transducer subunit
gp130 (Heinrich et al. 2003), and induces the second
messenger cascade. The inﬂammatory roles of IL-6 are
contradictory. IL-6 has been reported to be involved in
both pro-, and anti-inﬂammatory processes (Spooren et al.
2011). As an inﬂammatory cytokine, IL-6 plays a partic-
ularly important role in neuronal defensive mechanisms. It
has been reported that the overexpression of IL-6 promotes
astrogliosis and microgliosis in different in vivo models
(Fattori et al. 1995; Tilgner et al. 2001). On the other hand,
IL-6 is suggested to have an anti-inﬂammatory role, con-
tributing toward the maintenance of the blood–brain barrier
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(Milner and Campbell 2006). Other than being an inﬂam-
matory cytokine, IL-6 is also considered as a neurotrophic
factor. It has been shown to enhance neuronal differentia-
tion in different cell types (Cao et al. 2006; Sterneck et al.
1996; Zhang et al. 2007) and promote neurogenesis (Islam
et al. 2009). The exact role of IL-6 in neurological disor-
ders is yet to be fully understood; however, elevated IL-6
level has been associated with many neurological diseases,
including multiple sclerosis (Maimone et al. 1991),
dementia (Zuliani et al. 2007), Parkinson’s disease
(Nagatsu et al. 2000), autism, and schizophrenia (Patterson
2009). An in vivo study demonstrated that maternal
immune activation—a popular hypothesis regarding the
pathogenesis of neurodevelopmental disorders—failed to
induce the behavior changes associated with autism and
schizophrenia in IL-6
-/- mice offspring model compared
to that of the wild-type strain (Smith et al. 2007), indicating
the role of IL-6.
Cigarette smoking is not only a major risk factor for
airway diseases, but also for neurodegenerative disorders,
including Alzheimer’s disease (AD, Ronnemaa et al. 2011;
Barnes and Yaffe 2011). Cigarette smoke (CS) induces
oxidative damage in different ways. Free radicals generated
by CS induce lipid peroxidation, which can be measured by
its byproducts, 8-isoprostane and malondialdehyde (MDA,
Armstrong and Browne 1994). On the other hand, oxidant-
mediated protein damage can be determined by the level of
advanced oxidation protein products (AOPP, Witko-Sarsat
et al. 1996). The oxidative/anti-oxidative imbalance that is
triggered by long-term exposure to the abundant reactive
oxygen species (ROS) in CS is known to induce pro-
inﬂammatory cytokines, including IL-6 in the lung (Crapo
2003). It is unclear, however, whether exposure to CS
would lead to an elevated level of IL-6 in the cerebral
cortex secondary to oxidative/anti-oxidative imbalance.
We have previously found that serum cotinine, an
alkaloid found in tobacco that can be used as an indicator
for CS exposure and 8-isoprostane were signiﬁcantly
increased; lung superoxide dismutase (SOD) and catalase
activity were also elevated as a self-defensive response
after 56 days of CS exposure in our established subchronic
CS exposure rat model (Chan et al. 2009). SOD is
responsible for catalyzing the conversion of superoxide
anions into hydrogen peroxide (Zelko et al. 2002) which is
further decomposed into water and oxygen by catalase
(Chelikani et al. 2004). On the other hand, hydrogen per-
oxide is also removed by the reduced glutathione (GSH)
and oxidized glutathione (GSSG) system (Sies 1999).
Based on our previous ﬁndings in the lung, we hypothe-
sized that rat cerebral cortical levels of IL-6 would be
increased after CS exposure for 56 days through oxidative
pathway. We aimed to determine the cerebral cortical
levels of IL-6 and changes in local oxidative/anti-oxidative
markers using our established subchronic CS exposure rat
model.
The subchronic CS exposure rat model was previously
established in our group, and the protocol was published
elsewhere (Chan et al. 2009). This approach was attempted
to mimic the situation of secondary smoke exposure in
healthy subjects (Chow et al. 1996), from adolescent-
to-early adulthood in our study. In brief, 22 male Sprague–
Dawley (SD) rats (150–200 g, around 5–6 weeks old) were
purchased from the Laboratory Animal Unit (LAU) of The
University of Hong Kong and were randomly divided into
two groups. Cigarette smoking (CS) group was exposed
with 4% (v/v, smoke/air) CS (11 mg Tar, 0.8 mg Nicotine;
Camel; ﬁlter, R.J. Reynolds, Winston-Salem, NC, USA)
with the mouthpiece ﬁlter removed (by cutting the wrap-
ping paper circumferentially at the point where the glass-
ﬁber ﬁlter meets the tobacco leaves) for 1 h daily for 56
consecutive days, while SA control group was exposed to
fresh air (0%, v/v, smoke/air), simultaneously. After
56 days of exposure, the rats were euthanized by admin-
istering overdose of pentobarbitone. The cortex was dis-
sected and stored in -80C until further analysis. This
protocol was approved by the Committee on the Use of
Live Animals in Teaching and Research (CULATR) of The
University of Hong Kong. From our previous ﬁndings, the
mean value of serum cotinine in CS exposure group was
7.19 ± 0.80 ng/ml (mean ± SEM), cotinine was not
detected in serum of SA control group (Chan et al. 2009).
IL-6 mRNA expression was determined using semi-
quantitative RT-PCR method. Total RNA was extracted
from cerebral cortical tissues using TRI reagent (Molecular
Research Center, Inc., Cincinnati, OH, USA). cDNA was
generated by reverse-transcription as follows: total RNA
(1 lg) was added to a mixture of 59 RT buffer (USB Cor-
poration, Cleveland, OH, USA), dNTP (20 mM), Oligo dt
(1 lg, Invitrogen), RNaseOUT inhibitor (40 U, Invitrogen),
and M-MLV reverse transcriptase (400 U, USB Corpora-
tion, Cleveland, OH, USA), topped up to 40 ll with DEPC
water. The reaction mixture was incubated at 37C for
30 min, and then at 75C for 10 min. cDNA was stored at
4Cuntilfurtheranalysis.Genetranscriptlevelwasassessed
by PCR. Guanine nucleotide-binding protein b-polypeptide
2-like 1 (GNB2L1) mRNA expression served as an internal
control.Theprimerswere generated by Invitrogen (forIL-6,
forward primer: 50-CCTATTGAAAATCTGCTCTGGTC
TTCTGG-30, backward primer: 50-CTTCAAGTGCTTT-
CAAGATGAGTTGGATGG-30; for GNB2L1, forward
primer: 50-GAGTGTGGCCTTCTCCTCT-30, backward
primer: 50-GCTTGCAGTTAGCCAGGTT-30). For quanti-
tative analysis, band intensity was measured by software
ImageJ (NIH, Bethesda, ML, USA). Results are expressed
as target gene to GNB2L1 ratio.
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123Cerebral cortical tissues were lysed in ice-cold lysis
buffer containing phenylmethylsulfonyl ﬂuoride (1 mM)
and protease inhibitor cocktail (Sigma-Aldrich). Protein
concentration was determined by DC protein assay kit
(Bio-Rad, Richmond, CA, USA). Protein extracts were
separated in 8–15% SDS-PAGE gel and then transferred
onto a PVDF membrane. The membrane was blocked by
5% skim milk in Tris-buffered saline (pH 7.4) containing
0.1% Tween-20. Subsequently, blocked membrane was
incubated with diluted rabbit-anti-IL-6 (Abcam, 1:1,000),
goat-anti-ionized calcium binding adaptor molecule-1
(Iba-1) (Abcam, 1:1,000), mouse-anti-glial ﬁbrillary acidic
protein (GFAP) (Sigma, 1:1,000), rabbit-anti-gp130 (Santa
Cruz, 1:100), rabbit-anti-NOS1 (Santa Cruz, 1:200) or
rabbit-anti-SOD2 (Santa Cruz, 1:200) primary antibody at
4C overnight. The membrane was incubated with horse-
radish peroxidase (HRP)-conjugated goat-anti-rabbit, goat-
anti-mouse, or rabbit-anti-goat secondary antibody (Dako,
1:2,000) for 1 h at room temperature. Bands were visual-
ized on a Fuji X-ray ﬁlm (Fujiﬁlm, Tokyo, Japan) using an
enhanced chemiluminescence (ECL) kit. After developed
the target proteins, membranes were stripped and re-probed
for corresponding internal control. Quantitative analysis of
the chemiluminescent signal was done by software Image
J. The protein of interest-to-internal control ratio was cal-
culated. Results are expressed as fold of control.
Cortical MDA levels were measured by thiobarbituric
acid reactive substances (TBARS) assay kit (Cayman
Chemical) according to manufacturer’s instruction. The
change in absorbance was measured at wavelength
540 nm. The concentration of MDA corrected with protein
amount is expressed as fold of control.
Cortical AOPP levels were measured by spectrophoto-
metric detection method. 200 ll of cerebral cortical
homogenates or chloramin T (0–160 lM) were incubated
with 1.16 M potassium iodide (10 ll) for 5 min at room
temperature. The reaction was stopped by acetic acid
(20 ll). The change in absorbance was measured at
wavelength 340 nm. The concentration of AOPP corrected
with protein amount is expressed as fold of control.
The SOD activity in cerebral cortical homogenates was
measured with reference to the rate of cytochrome c
reduction. The protocol has previously been reported by
Chan et al. (2009). The rate of the change in absorbance
was measured at wavelength 550 nm. SOD activity cor-
rected with protein amount is expressed as fold of control.
The catalase activity in cerebral cortical homogenates
was determined based on their reaction with hydrogen
peroxide. The protocol has previously been reported by
Chan et al. (2009). Catalase activity corrected with protein
amount is expressed as fold of control.
Total GSH and GSSG concentrations were measured based
on a protocol established previously (Rahman et al. 2006).
For GSSG measurement, diluted cerebral cortical homog-
enates (25 ll in sodium phosphate buffer and 5% sulfo-
salicylic acid) were incubated with vinylpyridine (2 ll) at
room temperature for 1 h. The mixture was then incubated
with a master mix containing sodium phosphate buffer
(143 mM), EDTA (6.3 mM), nicotinamide dinucleotide
phosphate (NADPH, 2.39 mM), glutathione reductase, and
5,5-dithiobis-2-nitrobenzoic acid (DTNB, 10 mM) (Sigma-
Aldrich) in dark at room temperature for 30 min. The
absorbance was measured at wavelength of 405 nm. The
procedure for measuring total GSH was the same as
mentioned above, except that no incubation with 2-vinyl-
pyridine was performed. Reduced GSH was calculated by
subtracting the amount of GSSG from total GSH. The ratio
of the reduced GSH/GSSG was calculated, and the results
are expressed as fold of control.
The measurement for nitrite levels was performed as
follows: Cerebral cortical homogenates were incubated
with diluted 2,3-diaminonaphthalene (DAN) in the dark at
room temperature for 10 min. The reaction was stopped by
sodium hydroxide (1.4 M). Fluorometric signal was
detected by excitation and emission wavelengths at 380
and 460 nm, respectively. The nitrite levels corrected with
protein amount are expressed as fold of control.
The measurements for superoxide levels were per-
formed as follows: Cerebral cortical homogenates (20 lg)
were incubated with lucigenin (0.5 mM, Santa Cruz, CA,
USA) in PBS. The chemiluminescent signal was measured
immediately after the addition of lucigenin using a
microplate reader (FLUOstar Optima, BMG LABTECH,
Victoria, Australia). The chemiluminescent signal is
expressed as relative luminescence unit (RLU) per micro-
gram protein.
Numerical data are expressed as mean ± standard error
of the mean (SEM). Differences in parameters between
groups were analyzed by non-parametric Mann–Whitney
U test, with the use of the Statistical Program for the Social
Sciences (SPSS, edition 18.0). A p value less than 0.05
would be regarded as statistically signiﬁcant.
Our results demonstrated a signiﬁcant increase of both
IL-6 mRNA and protein levels in line with the protein level
of gp130 in the rat cerebral cortex after 56 days of CS
exposure (Fig. 1). The elevated protein level of gp130
indicated an increased binding of IL-6 to its receptor.
Activations of microglia and astrocytes have been associ-
ated with the brain inﬂammation and injury, which can be
induced by IL-6 (Balasingam et al. 1994). In our model, we
observed no signiﬁcant changes in the expression of Iba-1
or GFAP in cortex after CS exposure, which is consistent
with the earlier literature (Fig. 2, Fuller et al. 2010). These
ﬁndings suggest that the inﬂammatory pathway had not yet
been activated even when IL-6 levels were elevated in our
model.
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123To determine the local oxidative response in the cortex,
the MDA and AOPP levels were measured. Our results
showed no signiﬁcant changes in the cortical MDA (6.5 ±
1.1 nmol/mg protein for control values) or AOPP (47.7 ±
12.6 nmol/mg protein for control values) levels after
56 days of CS exposure (Fig. 3a, b), indicating no oxidative
burden.
We further investigated the changes in different anti-
oxidative markers in the cortex. We found that there was
a signiﬁcant reduction of total SOD activity (201.5 ±
82.7 mU/mg protein for control values) after CS expo-
sure, in agreement with the earlier literature (Luchese
et al. 2009), but not catalase activity (4.9 ± 0.6 U/mg
protein for control values). Furthermore, no signiﬁcant
changes in GSH/GSSG ratio were observed after 56 days
CS exposure (Fig. 3c–e). For further investigation of
whether the decreased SOD activity would be due to
reduction of its protein level, the protein level of man-
ganese (Mn)SOD was determined after CS exposure. Our
result demonstrated that CS reduced the protein level of
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Fig. 1 Induction of IL-6 in cortex after 56 days of CS exposure.
a Expression of IL-6 mRNA, with GNB2L1 serving as an internal
control. b Quantitative analysis of luminescent band intensity of IL-6.
Results are expressed as IL-6 to GNB2L1 ratio. c Protein levels of
IL-6 and gp130, with b-actin serving as an internal control.
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of CS exposure. a MDA level, b AOPP level, c SOD activity,
d catalase activity, e the GSH/GSSG ratio, and f nitrite level
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123MnSOD (Fig. 4a, c). SOD is the ﬁrst line of anti-oxida-
tive enzyme that is responsible for the defensive mecha-
nism against ROS and other superoxide anion-free
radicals (Zelko et al. 2002). The reduction of SOD
activity might lead to the accumulation of superoxide
anions in the brain. To conﬁrm this, we examined the
superoxide levels in the cerebral cortex after CS exposure
by chemiluminescence assay. We found that the super-
oxide levels were signiﬁcantly higher in the cortex
(5.1 ± 1.9 RLU/lg protein versus 45.4 ± 6.0 RLU/lg
protein) after CS exposure (Fig. 4d). The increased
superoxide anions level can react with nitrogen species to
form peroxynitrite which is a more potent oxidant
involved in the nitration process of SOD. Post-transla-
tional modiﬁcations, including phosphorylation and
nitration of SOD, have been associated with the reduced
activity of SOD (Yamakura and Kawasaki 2010). The
question as to whether these mechanisms are involved in
the reduction of SOD activity in our model requires fur-
ther investigation.
Nitrite levels are associated with oxidative stress in the
rat brain (Vatassery et al. 2004). Intrahippocampal injec-
tion of IL-6 has been shown to induce nitrite levels (Ma
and Zhu 2000). In contrast, we observed a decreased nitrite
level in the cortex (74.5 ± 17.7 pmol/mg protein for con-
trol values, Fig. 3f) even with the increased IL-6 levels
after 56 days of CS exposure. The reduced nitrite level may
be explained by the decreased protein level of nNOS after
CS exposure (Fig. 4a, b). On the other hand, inactive
astrocytes and microglia may also explain the reduced level
of nitrite after CS exposure, as active astrocytes and
microglia are known to be responsible for the increased
production of nitrite during inﬂammation (Storer et al.
2005).
CS has been shown to induce pro-inﬂammatory cyto-
kines via nicotinic and oxidative pathways in dendritic
cells (Vassallo et al. 2008). It is unclear as to whether the
increased IL-6 levels in our in vivo model are mediated by
the nicotinic pathways, which requires further investiga-
tion. Unlike what we found previously in the lung, our data
appear to reject the hypothesis that CS-induced IL-6 is
mediated by the oxidative/anti-oxidative imbalance in the
cortex of our subchronic CS exposure in vivo model;
however, it is unclear as to whether sustained exposure to
CS in a chronic manner would trigger oxidative burden in
the brain. Furthermore, our interpretations are limited by
the age of the rats, since oxidative/antioxidative imbalance
is more severe in an aged brain (Venkateshappa et al.
2011); hence, studies involving different age groups of rats
would be required for better understanding on the dynamic
oxidative changes at different ages. It is also noteworthy
that, since all measurements were carried out in protein
samples extracted from the whole cerebral cortex, the
changes in IL-6 levels and oxidative/anti-oxidative markers
in different cortical regions could not be assessed.
In conclusion, our data demonstrated that CS exposure
elevated IL-6 in the rat cortex; however, in contrary to data
obtained from our pulmonary studies, ‘‘oxidative/anti-oxi-
dative imbalance’’ is not the mechanism involved in the
cortex of our in vivo rat model in early adulthood. The
increased IL-6 caused by CS, together with the reduction of
nitrite levels, may alter brain function. Furthermore,
reduced SOD activity after exposure to CS could play a
role in neurodegeneration. More studies are warranted to
elucidate the underlying mechanisms on CS-mediated IL-6
induction and the effect of elevated IL-6 in the brain.
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